NAME: Adelaide Hebert, MD
POSITION TITLE: Professor
A. Personal Statement
I have served as chief of Pediatric Dermatology at UT Health McGovern Medical School and Memorial Hermann since 1986. My career in clinical research began in 1987 with the initiation of multiple clinical trials across a wide spectrum of dermatologic conditions encompassing atopic dermatitis, psoriasis, hyperhidrosis, alopecia areata, skin and soft tissue infections, acne, rosacea, diaper dermatitis and seborrheic dermatitis. As the only clinical researcher at UT Health Medical School-Houston in the Department of Dermatology, I am responsible for both overseeing and conducting numerous clinical trials and running a clinical research team. In the 36 years in which I have conducted clinical trial work, I have been involved in over 165 clinical trials which range from phase I to phase IV, investigator-initiated trials and trials funded by the Department of Defense and the NIH. My personal interest in conducting this clinical trial is related to the broad experience I have had in managing patients with alopecia areata from a wide variety of ethnicities, each with their unique challenges and responses to available therapy. My hope is to expand the scope and understanding of alopecia areata in these diverse populations to allow more focused and individualized treatment regimens for the patients I see on a daily basis in the outpatient clinic setting.
Executed Clinical Trials of Interest: Role Principal Investigator
1. A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS Pfizer B7981015
2. A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA Pfizer B7981032
3. A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS. Pfizer B7451014
4. A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS
B. Positions and Honors
Positions and Employment
1986- Present Chief of Pediatric Dermatology, UT Health McGovern Medical School
1986-Present Chief of Pediatric Dermatology, Memorial Hermann Children’s Hospital
1986-1992 Assistant Professor, The University of Texas Health Science Center at Houston, TX
1992-1996 Associate Professor, The University of Texas Health Science Center at Houston, TX
1996-Present Professor, The University of Texas Health Science Center at Houston, TX
Other Experience and Professional Memberships
1982-Present Member, American Academy of Dermatology
2019-Present Board of Directors, American Academy of Dermatology
1982-Present Member, Women’s Dermatologic Society
2016-2017 President, Women’s Dermatologic Society
1984-Present Member, Society for Pediatric Dermatology
2006-2007 President, Society for Pediatric Dermatology
2000-Present Member, American Dermatology Association
2020 Robert G. Freeman Award, Texas Dermatologic Society
2009-2021 Castle Connolly Top Doctor Award
C. Contribution to Science
My early and current career have been focused on atopic dermatitis, a chronic relapsing skin disorder that affects 1 out of 5 school aged children in the united states. When I entered dermatology residency the only available FDA approved medications for atopic dermatitis were topical steroids. Numerous early clinical trials involved studying a variety of formulations of topical steroids and their impact on the HPI-Axis in children in young as three months of age. Enlarging the scope of science and availability of drugs for this youngest most vulnerable age group allowed innumerable patients to receive safe and much needed therapy to help control their atopic dermatitis. Since that time, emerging therapies for atopic dermatitis have included topical tacrolimus, pimecrolimus, crisaborole and dupilumab. I have participated as a researcher or as part of a data safety monitoring board for each of these available medications approved for this disease state. Three recent clinical trials using newer therapeutic options encompass JAK inhibitors and a new PDE-4 Inhibitor, each of which appears promising for the patients suffering with atopic dermatitis.
1. Hebert A, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Combination of
desoximetasone 0.25% and Tacrolimus 0.1% ointments for the treatment of
atopic dermatitis. 63rd AAD Annual Meeting – New Orleans, LA, February 8 – 22, 2005.
2. Hebert AA, Warken KA, Cherill, R. Pimecrolimus cream 1%:a new development in nonsteroid topical treatment of inflammatory skin diseases. Seminars in Cutaneous Medicine and Surgery, 20, (4) December:260-267, 2001.
3. Hebert AA. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Clin Ther 2006 Dec; 28(12):1972-1982.
4. Spergel JM, Boguniewicz M, Paller AS, Hebert AA, et al. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol 2007 Aug; 157(2):378-381.
5. Luger T, Boguniewicz M, Hebert AA, et al. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015 Jun;26(4):306-15. doi: 10.1111/pai.12331. Epub 2015 Apr 13.
6. Luger T, Boguniewicz M, Carr W, Hebert AA, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306-315.
7. Hebert A: Pimecrolimus (Elidel®, SDZ ASM 981):Summary of Clinical Profile. EADV Satellite Symposium: ”The Long-Term Management of Atopic Dermatitis”. Munich, Germany, October 11, 2001.
8. Hebert A: Pimecrolimus: Bringing new efficacy to the short-term management of atopic eczema. Novartis Pharma AG Symposium - Miami, Florida, April 19-21, 2002.
9. Boguniewicz M, Paller A, Hebert AA. Efficacy and Safety of Crisaborole Topical Ointment, 2%, A Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase Inhibitor in 2 Phase 3 Studies in Children and Adults with Mild-to-Moderate Atopic Dermatitis. American Academy of Allergy and Immunology.
10. Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, Stein Gold LF, Van Syoc M, Zane LT, Tschen E. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017 Oct;77(4):641-649.e5. doi: 10.1016/j.jaad.2017.06.010. Epub 2017 Aug 18. PubMed PMID: 28823881.
11. Zane LT, Kircik L, Call R, et al. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatr Dermatol. 2016;33(4):380-387.
12. Paller AS, Tom WL, Lebwohl MG, Hebert AA, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11.J Am Acad Dermatol. 2016.
Psoriasis is a new diagnosis for over 20,000 children in the united states every year. Despite this disease prevalence until recently only six available therapies were FDA approved for children with psoriasis. Of these three were topical agents of various formulations and three were biologic therapies. Only in may of 2021 was an additional biologic agent added for those patients six years of older who suffer with psoriasis. For this reason our clinical research team has undertaken ten protocols that focus on psoriasis within the pediatric population. Three of these are currently enrolling patients ages six years of age and up. Clinical trials in psoriasis are also have been and will continue to be conducted within the adult realm.
1. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I,Hebert AA, Eichenfield AF, Patel V, Creamer K, Jahreis A. Etanercept treatment for children and adolescents with plaque psoriasis. New Engl J Med 2008 Jan; 358:241-251
2. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad of Dermatol 2011 Jan; 64(1):64-70.
3. Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, Siegfried E, Silverberg N, Cordoro KM. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018 Mar;35(2):170-181. doi: 10.1111/pde.13382. Epub 2018 Jan 4. PubMed PMID: 29314219.
4. Cook-Bolden FE, Hebert AA, Guenthner ST, Kang R, Martin G, Jacobson A. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants. J Drugs Dermatol. 2020 Aug 1;19(8):747-754. doi: 10.36849/JDD.2020.5250. PMID: 32845589.
5. Hebert, A., Schrieber, R., Glaab, D., & Eichenfield, L. (2020). Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 4(6), s77–. https://doi.org/10.25251/skin.4.supp.77
6. Hebert A: Topical steroids, anthralin, and tar therapy of psoriasis. J. Geriatric Dermatology 3(Suppl B):21B-27B, 1995.
7. Fowler JF Jr, Hebert AA, Sugarman J. DFD-01, a novel medium potency betamethasone diproprionate 0.05% emollient spray, demonstrates similar efficacy to augmented betamethasome diproriane 0.05% lotion for the treatment of moderate plaque psoriasis. J Drugs Dermatol 2016 Feb; 15(2): 154-62.
D. Additional Information: Investigator Initiated Protocols with multidisciplinary teams
1. Sirolimus for the treatment of Vascular Anomalies: an Effectiveness and Safety Pilot Study
1. Kothamasu VS, Turner KD, Hebert AA, Atkinson A, Greives MR. Sirolimus as a treatment modality for Kaposiform Hemangioendothelioma. Texas Society of Plastic Surgery, Galveston, TX. November 2019.
2. Atkinson A, Turner K, Hebert A, Cox C, Zvanvajanja R, Greives MR. Difficult Case: Mediastinal Vascular Malformation in the Setting of a Systemic Disease. International Society for the Study of Vascular Anomalies. Vancouver BC May 2020.
3. Zvavanjanja, R, Rasmussen J, Hebert A, Sevick E, Greives MR. A Feasibility Study to Demonstrate the Use of Near Infrared Fluorescent Lymphatic Imaging (NIRFLI) to Diagnose and Direct Treatment in Pediatric Patients with Lymphatic Anomalies. 2019 SIR 44th Annual Scientific Meeting. Austin TX. March 2019.
1. A multi-center, prospective, randomized, double-blind, placebo controlled evaluation of the topically applied rapamycin to cutaneous angiofibromas in subjects with TSC. Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex. A Department of Defense Tuberous Sclerosis Research Program of the Office of the Congressionally Directed Medical Research Programs, $1.2 million, September 2011-August 2014.
1. Nguyen Q, Vu M, Chen L, Hebert A. Current and Emerging Medical Therapies for Cutaneous Manifestations of Tuberous Sclerosis Complex. American Academy of Dermatology Annual Meeting, Washington, DC, March 1 - 5, 2019.
2. Pacha O, Hebert A.A.(Pending Publication) “Tuberous Sclerosis.” in Acneiform Eruptions in Dermatology: A Differential Diagnosis, ed. Joshua Zeichner New York: Springer Clinical Sciences p 229-233.
3. Northrup H, Etzel FK, Hebert AA Johnston DA, Delgado MR, Roach ES: Tuberous sclerosis complex: a clinical survey of 110 patients. 1997.
4. Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, Northrup H. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R.D. 2012 Sep 1; 12(3): 121-6
5. Teng JM, Cowen EW, Wataya-Kaneda M, Gosnell ES, Witman PM, Hebert AA, Mlynarczyk G, Soltani K, Darling TN. Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA Dermatol. 2014 Jul 16
6. Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, Tate P, Northrup H; TREATMENT Trial Collaborators.. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial. JAMA Dermatol. 2018 Jul 1;154(7):773-780. doi: 10.1001/jamadermatol.2018.0464. PubMed PMID: 29800048.
7. Nguyen QD, DarConte MD, Hebert AA. The cutaneous manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):321-325.
1. Afinitor for treatment of disfiguring cutaneous lesions in Neurofibomatosis 1
CRAD001CUS232T & Molecular Modeling of Neurofibromatosis Response to mTOR Inhibition to Uncover Targets for Treatment
2. NFlection Therapeutics, Protocol Number NFX-179-NF1-202 entitled "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas.
1. Slopis JM, Arevalo O, Bell CS, Hebert AA, Northrup H, Riascos RF, Samuels JA, Smith KC, Tate P, Koenig MK.. Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial. Drugs R D. 2018 Dec;18(4):295-302.